Method of variability optimization in pharmacokinetic data analysis

被引:0
作者
Tomasz Grabowski
Jerzy Jan Jaroszewski
Walerian Piotrowski
Małgorzta Sasinowska-Motyl
机构
[1] Polpharma Biologics,Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine
[2] University of Warmia and Mazury,Biostatistical Laboratory, Department of Epidemiology
[3] Cardiovascular Disease Prevention and Health Promotion Institute of Cardiology,Departmentof Pharmacodynamics
[4] Medical University of Warsaw,undefined
来源
European Journal of Drug Metabolism and Pharmacokinetics | 2014年 / 39卷
关键词
Standard deviation; Sampling; Variability; Pharmacokinetics;
D O I
暂无
中图分类号
学科分类号
摘要
For many drugs administered per os, high variability in the concentration–time (C–T) values from first sampling to the phase of distribution may cause difficulty in pharmacokinetic analysis. Therefore, the aim of this study was to propose a method of transformation of C–T data, which would allow significantly reducing the standard deviation (SD) value of observed concentrations, without a statistically significant influence on the value of the mean for each sampling point in group. In the presented study, the lowest value of relative standard deviation of concentrations observed in the elimination phase and the value of precision of the used analytical method, were used to optimize the arithmetic, geometric means, median, and the value of SD obtained after single oral administration of itraconazole in human subjects. Non-compartmental modeling was used to estimate pharmacokinetic parameters. The analysis of SD pharmacokinetic parameters after C–T value optimization indicated more than twice the lower value of SD. After transforming the itraconazole data, lower variability of concentration data gives more selective pharmacokinetics profile in absorption and early distribution phase.
引用
收藏
页码:111 / 119
页数:8
相关论文
共 115 条
[1]  
Abdallah HY(1998)An area correction method to reduce intrasubject variability in bioequivalence studies J Pharm Pharm Sci 1 60-65
[2]  
Chien JY(2005)Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation AAPS J 7 E544-E559
[3]  
Friedrich S(2010)Effect of gastric emptying and entero-hepatic circulation on bioequivalence assessment of ranitidine Methods Find Exp Clin Pharmacol 32 413-419
[4]  
Heathman MA(1980)Pitfalls and valid approaches to pharmacokinetic analysis of mean concentration data following intravenous administration J Pharmacokinet Biopharm 6 539-552
[5]  
de Alwis DP(2002)Absolute bioavailability of [14C] genistein in the rat; plasma pharmacokinetics of parent compound, genistein glucuronide and total radioactivity Eur J Drug Metab Pharmacokinet 27 249-258
[6]  
Sinha V(2000)Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes Br J Clin Pharmacol 49 223-230
[7]  
Chrenova J(2008)Highly variable drugs: observations from bioequivalence data submitted to the FDA for new generic drug applications AAPS J 10 148-156
[8]  
Durisova M(1998)Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies Eur J Pharm Sci 6 259-264
[9]  
Mircioiu C(2006)Comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs J Clin Pharmacol 46 674-692
[10]  
Dedik L(2009)Chromatographic/mass spectrometric method for the estimation of itraconazole and its metabolite in human plasma. Application to a bioequivalence study Arzneimittelforschung 8 422-428